T. Rowe Price Associates
LUCD icon

T. Rowe Price Associates’s Lucid Diagnostics LUCD Stock Holding History

T. Rowe Price Associates’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$86K Buy
74,377
+39,241
+112% +$49.9K ﹤0.01% 3025
2025
Q4 		$39K Hold
35,136
– – ﹤0.01% 3059
2025
Q3 		$36K Hold
35,136
– – ﹤0.01% 3023
2025
Q2 		$41K Buy
+35,136
New +$45.4K ﹤0.01% 3021

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

T. Rowe Price Associates's LUCD Position: Q1 2026 in Review

T. Rowe Price Associates increased its Lucid Diagnostics (LUCD) stake by 112% in Q1 2026, buying an estimated $49.9K and bringing the position to 74,377 shares worth $86K. The position accounts for ﹤0.01% of the portfolio, ranked #3025.

T. Rowe Price Associates first reported a position in LUCD in Q2 2025 and has held it in 4 quarters since. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • T. Rowe Price Associates held 74,377 shares of Lucid Diagnostics worth $86K as of Q1 2026.
  • T. Rowe Price Associates bought 39,241 Lucid Diagnostics shares in Q1 2026, an estimated $49.9K.
  • Lucid Diagnostics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #3025 holding.
  • T. Rowe Price Associates first reported a position in Lucid Diagnostics in Q2 2025 and has held it in 4 quarters since.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.